Other

Senju Pharmaceutical Co., Ltd.

Seed Company Limited

Shinichi Yasueda

Takao Sato

Takahiro Ogawa

Haruka Obata

Katsuhiro Inada

Yoshiko Yamazaki

Toru Matsunaga

Masazumi Yamaguchi

Wakiko Asayama

Yoshinori Ii

Tadashi Terai

Kiyoshi Shoji

The purpose of the present invention is to provide a polymer gel that can increase drug content ratio and reduce undesirable influence on gel strength and shape stability after the drug release, compared with the conventional techniques. The purpose can be achieved by an anionic drug-containing medical device comprising: (1) an anionic drug; and (2) a copolymer which contains, as constituents, a cationic monomer comprising a condensation product of an alkyl quaternary ammonium compound having a substituted or unsubstituted aralkyl group and (meth)acrylic acid or a salt of the condensation product and a monomer capable of copolymerizing with the condensation product or the salt of the condensation product.

Anionic drug-containing medical device

There is provided an aqueous liquid pharmaceutical composition which comprises Gatifloxacin (chemical nomenclature: (&plusmn;)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinoline carboxylic acid) or its salt and disodium edetate. Further, there are provided a method for raising corneal permeability of Gatifloxacin, a method for preventing precipitation of Gatifloxacin crystals, and a method for preventing coloration of Gatifloxacin by incorporating disodium edetate into an aqueous liquid preparation containing Gatifloxacin or its salt.

Aqueous liquid pharmaceutical composition comprised of gatifloxacin

In order to promote solubilization or suspension of 4-oxo-8-&lsqb;4-(4-phenylbutoxy)benzoylamino&rsqb;-2-(tetrazol-5-yl)-4H-1-benzopyran or its hydrate (pranlukast) in water, at least one component selected from surfactants, water-soluble cellulose derivatives and water-soluble vinyl polymers is formulated together with pranlukast. Thus, it is possible to provide an aqueous liquid pharmaceutical composition containing higher concentration of pranlukast and having good properties.

Aqueous liquid pharmaceutical composition containing as main component benzopyran derivative

Growing community of inventors

Kobe, Japan

Shinichi Yasueda